NEWS RELEASE
`
`
`New hope in advanced prostate cancer:
`Alberta, Saskatchewan and Ontario fund
`coverage for JEVTANA® (Cabazitaxel)
`
`Therapy provides significant survival benefit in second-line metastatic hormone-refractory prostate
`cancer in combination with prednisone.
`
`Laval, Canada, October 4, 2012 – Sanofi is pleased to announce that the provinces of Alberta,
`Saskatchewan and Ontario have listed JEVTANA® (cabazitaxel) on their respective provincial formularies
`so that it is now eligible for reimbursement for patients with advanced prostate cancer. JEVTANA®
`(cabazitaxel) is indicated as a second line treatment for castration resistant (hormone refractory)
`metastatic prostate cancer (mHRPC) in combination with prednisone in patients who have received prior
`treatment with a docetaxel containing regimen.
`
` “JEVTANA fills a critical treatment gap, since it is the novel treatment approved for patients with this
`stage of metastatic hormone-refractory prostate cancer. The ability to access JEVTANA and to know that
`Alberta, Saskatchewan and Ontario are funding the treatment is a major gain for men dealing with the
`disease and their families,” said Dr. Stan Glezer, Vice President of Evidence, Value and Access. “Sanofi is
`strongly committed to bringing innovative therapies to the cancer community and to working in
`cooperation with the provincial health agencies to demonstrate the value of medicine for the patients
`and contribute to the sustainability of the healthcare system.”
`
`The combination of JEVTANA® and prednisone is the first and only chemotherapy to have shown a
`significant survival benefit for men with mHRPC previously treated with a docetaxel-containing
`regimen.
`
`Reimbursement for prescription drugs is not mandated by the Canada Health Act or any other federal
`legislation. Provincial governments independently establish reimbursement plans.
`
`“We trust other provinces will follow the lead of Alberta, Saskatchewan and Ontario and approve
`coverage of this treatment option,” added Dr. Glezer. “JEVTANA is an important therapy addition for
`patients living with mHRPC and helps healthcare professionals in their efforts to treat those patients.
`Hopefully the availability of a drug like JEVTANA® (cabazitaxel) will signal the start of a new, more
`effective approach to help these patients access the treatment."
`
`"Access and availability in Alberta to new options such as JEVTANA® can provide patients with a better
`chance of survival when dealing with such a difficult illness,” concluded Bob Shiell, Executive Director,
`Prostate Cancer Canada Network (PCCN) Calgary.
`
`About JEVTANA®
`JEVTANA® (cabazitaxel) is approved as a second-line treatment option for metastatic castration resistant
`(hormone-refractory) prostate cancer (mCRPC).[i] JEVTANA® is a chemotherapy compound used with the
`steroid medicine prednisone or prednisolone to treat people with mCRPC previously treated with a
`docetaxel-containing treatment regimen.[ii]
`
`Jevtana® is a registered trademark of Sanofi.
`
`AVENTIS EXHIBIT 2044
`Mylan v. Aventis
`IPR2016-00627
`
`1
`
`

`
`
`About Prostate Cancer
`Worldwide, prostate cancer ranks third in cancer incidence and sixth in cancer mortality in men. In the
`U.S., prostate cancer remains the second most common cause of cancer death among men after lung
`cancer. In Canada, one man in seven men will develop prostate cancer. It is the most frequently
`diagnosed cancer in men and its incidence has increased by 30 percent since 1988. While it is most
`commonly diagnosed after age 70, prostate cancer can also occur in men in their forties and fifties. [iii]
`For many patients with prostate cancer, their disease continues to progress despite prior treatment –
`including surgical and/or hormonal castration followed by chemotherapy. Metastatic prostate cancer
`indicates that the cancer has spread to the lymph nodes or other parts of the body, particularly the
`bones. Castration resistant/hormone-refractory prostate cancer means that the cancer has continued to
`grow despite the suppression of male hormones that fuel the growth of prostate cancer cells. An
`estimated 10-20% of patients with prostate cancer are diagnosed when the cancer has already
`metastasized.
`
`About Sanofi
`Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic
`solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven
`growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
`emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in
`New York (NYSE: SNY).
`
`Sanofi companies in Canada include sanofi-aventis Canada Inc. (pharmaceuticals), Sanofi Pasteur
`(vaccines), Sanofi Consumer Health (health and beauty), Genzyme (rare diseases) and Merial (animal
`health). Together they employ more than 1,700 people, mainly in the greater Montreal and Toronto
`areas. In 2011 Sanofi companies invested $151.7 million in R&D in Canada, creating jobs, business and
`opportunity throughout the country. For additional information, please visit http://www.sanofi.ca .
`
`
`– 30 –
`
`For further information:
`MEDIA
`Caroline Martel
`Communications Consultant, Sanofi Canada
`514-956-6120
`caroline.martel@sanofi.com
`
`
`
`
`[i] “About Jevtana.” Sanofi-aventis Oncology. Available online: https://www.sanofi-
`aventisoncology.com/wps/portal/oncology/products/jevtana. Accessed 2/23/2011.
`[ii] “About Jevtana.” Sanofi-aventis Oncology. Available online: https://www.sanofi-
`aventisoncology.com/wps/portal/oncology/products/jevtana. Accessed 2/23/2011.
`[iii] Prostate Cancer: Understand the Disease and its Treatment: Saad F, McCormack M; Annika Parance Publishing;
`2012, p. 25
`
`2